Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tau topography subtypes account for clinical heterogeneity and longitudinal trajectories in early-onset Alzheimer's disease.

Brain communications·2026
Same author

Cognitive dispersion profiles and prediction of cognitive change in early-onset dementias: Results from LEADS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Criterion and convergent validity of plasma biomarkers in early-onset Alzheimer's disease: Initial findings from LEADS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Factors influencing accelerated progression in behavioral variant frontotemporal dementia.

Journal of neurology·2026
Same author

Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia.

Neurology open access·2026
Same author

Distinct Tau PET Dynamics in Early vs. Late Age-of-Onset Alzheimer's disease.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jun 26, 2026

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

Frontotemporal dementia: therapeutic interventions.

Mario F Mendez

    Frontiers of Neurology and Neuroscience
    |February 3, 2009
    PubMed
    Summary

    Frontotemporal dementia (FTD) management relies on psychoactive drugs like SSRIs and trazodone to control behavioral symptoms. Research is progressing towards targeted therapies for this early-onset dementia.

    Area of Science:

    • Neurology
    • Geriatrics
    • Pharmacology

    Background:

    • Frontotemporal dementia (FTD) presents with diverse behavioral symptoms, complicating management.
    • Current FTD treatments primarily involve symptomatic relief with psychoactive medications.
    • There are no FDA-approved disease-modifying treatments for FTD.

    Purpose of the Study:

    • To review current pharmacological and non-pharmacological management strategies for FTD.
    • To discuss emerging research directions for rational drug therapy in FTD.
    • To highlight the development of outcome measures and treatment targets for FTD clinical trials.

    Main Methods:

    • Review of existing literature on FTD management.
    • Analysis of the efficacy of various drug classes, including SSRIs, trazodone, and antipsychotics.

    Related Experiment Videos

    Last Updated: Jun 26, 2026

    A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
    06:22

    A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

    Published on: September 3, 2021

  • Discussion of non-pharmacological interventions and caregiver support.
  • Examination of ongoing research into novel therapeutic targets (e.g., tau, TDP-43) and clinical trial methodologies.

    • Main Results:

    • Selective serotonin reuptake inhibitors (SSRIs) can mitigate disinhibition, impulsivity, repetitive behaviors, and eating disorders in FTD.
    • Low-dose trazodone or atypical antipsychotics may help manage agitation and disturbed behavior.
    • Acetylcholinesterase inhibitors show limited efficacy in FTD, while memantine is under investigation.
    • Non-pharmacological approaches, including education and behavioral interventions, are crucial components of care.

    Conclusions:

    • Current FTD management is primarily symptomatic, focusing on behavioral control with available medications.
    • Developing standardized outcome measures and identifying specific molecular targets are critical steps toward effective FTD treatments.
    • Research into rational drug therapy, targeting proteins like tau and TDP-43, offers significant promise for future FTD interventions.